LIFECORE BIOMEDICAL, INC. DE LFCR
NasdaqSmall CapHealthcare
13F Pro quality score
Rank #2,529 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reading the latest SEC filing…
13F Pro quality score
Rank #2,529 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
LIFECORE BIOMEDICAL, INC. DE (LFCR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LFCR at 28.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,529 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (14.3) and profitability (15.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2027), LIFECORE BIOMEDICAL, INC. DE reports quarterly revenue of $34.2M, net income of $-6.2M, an operating margin of 7.5%. LFCR trades on the Nasdaq exchange and files with the SEC under CIK 1005286. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LFCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LIFECORE BIOMEDICAL, INC. DE directly from SEC EDGAR.